Protective effect of ADF in reperfusion injury after canine by transplantation

ADF对犬移植术后再灌注损伤的保护作用

基本信息

  • 批准号:
    06671340
  • 负责人:
  • 金额:
    $ 0.45万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
  • 财政年份:
    1994
  • 资助国家:
    日本
  • 起止时间:
    1994 至 1995
  • 项目状态:
    已结题

项目摘要

Human thioredoxin, which was previously recognized as adult T-cell leukemia-derived factor, has many physiologic activities, one of which is a radical scavenger effect. Its ability to reduce reperfusion injury was assessed in vivo in a canine lung transplantation model. In 19 dogs, left lung allotransplantation was performed after 100 minutes of warm ischemia. The function of the transplanted lung was assessed after clamping of the contralateral pulmonary artery. In the human thioredoxin group (n=6), human thioredoxin 30 mg/kg was given to the recipients during reperfusion. In the N-acetylcysteine group (n=5), N-acetylcysteine 150 mg/kg, known as a radical scavenger, was given in the same manner. In both groups, arterial oxygen tension was significantly higher than in the control group (n=8). In the human thioredoxin group, peak inspiratory pressure was significantly lower than in the control group. Macroscopic and microscopic examinations showed an almost normal appearance of the lung tissues in the human thioredoxin and N-acetylcysteine groups, in contrast to the abnormal findings in the control group. Thus it would appear that human thioredoxin has a protective effect on transplanted lungs, as does N-acetylcysteine, and that its action may be a radical scavenger effect.
人硫氧还蛋白是先前公认的成人T细胞白血病衍生因子,具有多种生理活性,其中之一就是清除自由基的作用。在犬肺移植模型中,对其减轻再灌注损伤的能力进行了体内评估。19只犬在热缺血100分钟后行同种异体左肺移植。阻断对侧肺动脉后评估移植肺功能。人硫氧还蛋白组(n=6),受体在再灌流期间给予人硫氧还蛋白30 mg/kg。N-乙酰半胱氨酸组(n=5)给予自由基清除剂N-乙酰半胱氨酸150 mg/kg。两组动脉血氧分压均显著高于对照组(n=8)。人硫氧还蛋白组吸气峰压显著低于对照组。肉眼和显微镜检查显示,人硫氧还蛋白和N-乙酰半胱氨酸组的肺组织外观几乎正常,与对照组的异常发现形成对比。因此,与N-乙酰半胱氨酸一样,人类硫氧还蛋白对移植肺具有保护作用,其作用可能是自由基清除剂作用。

项目成果

期刊论文数量(26)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
K.Yagi.et al.: "Inhibition of reperfusion injury by human thioredoxin(adult T-cell leukemia-derived facttor)in canine lung transplantation" J.Thorac.Cardiovasc.Sivg. 108. 913-21 (1994)
K.Yagi.et al.:“人硫氧还蛋白(成人 T 细胞白血病衍生因子)在犬肺移植中抑制再灌注损伤”J.Thorac.Cardiovasc.Sivg。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Yagi K, et al: "Inhibition of reperfusion injury by human thioredoxin(adult T-cell leukemia-derived factor)in canine lung transplantation." J Thorac Cardiovasc Surg. 108. 221-910 (1994)
Yagi K 等人:“人硫氧还蛋白(成人 T 细胞白血病衍生因子)在犬肺移植中抑制再灌注损伤。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YOKOMISE Hiroyasu其他文献

YOKOMISE Hiroyasu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YOKOMISE Hiroyasu', 18)}}的其他基金

The novel therapeutic approach for emphysema by regeneration of microvessel and alveolus after intrapulmonary arterial administration of gelatin microspheres slowly releasing basic fibroblast growth factor(bFGF-GMS).
肺动脉内给予缓慢释放碱性成纤维细胞生长因子(bFGF-GMS)的明胶微球后,通过再生微血管和肺泡来治疗肺气肿的新方法。
  • 批准号:
    21390393
  • 财政年份:
    2009
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The experimental study of the newly developed empyema treatment using self-tissue regeneration
新开发的自组织再生治疗脓胸的实验研究
  • 批准号:
    17390383
  • 财政年份:
    2005
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The experimental study of the induction of tissue regeneration filling in the thoracic cavity using the bioabsorbable materials slowly releasing growth factors.
利用生物可吸收材料缓释生长因子诱导胸腔组织再生充盈的实验研究。
  • 批准号:
    15390418
  • 财政年份:
    2003
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)

相似海外基金

A novel treatment for REBOA complications: Hydrogen gas inhalation therapy to alleviate oxidative stress due to ischemia-reperfusion injury
REBOA并发症的新型治疗方法:氢气吸入疗法减轻缺血再灌注损伤引起的氧化应激
  • 批准号:
    23K21458
  • 财政年份:
    2024
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation
开发合成肝素以保护移植肝免受移植过程中的缺血再灌注损伤
  • 批准号:
    10759102
  • 财政年份:
    2023
  • 资助金额:
    $ 0.45万
  • 项目类别:
Nck1 in Ischemia Reperfusion Injury
Nck1在缺血再灌注损伤中的作用
  • 批准号:
    10715406
  • 财政年份:
    2023
  • 资助金额:
    $ 0.45万
  • 项目类别:
The Role of Neutrophils in Ischemia/Reperfusion Injury following Acute Stroke
中性粒细胞在急性中风后缺血/再灌注损伤中的作用
  • 批准号:
    10606952
  • 财政年份:
    2023
  • 资助金额:
    $ 0.45万
  • 项目类别:
Zinc Protection Against Ischemia-Reperfusion Injury in Heart
锌可预防心脏缺血再灌注损伤
  • 批准号:
    10652915
  • 财政年份:
    2023
  • 资助金额:
    $ 0.45万
  • 项目类别:
Ischemia/Reperfusion injury and Myocardial edema
缺血/再灌注损伤和心肌水肿
  • 批准号:
    10718260
  • 财政年份:
    2023
  • 资助金额:
    $ 0.45万
  • 项目类别:
Role of Gasdermin D/E in intestinal ischemia-reperfusion injury
Gasdermin D/E 在肠缺血再灌注损伤中的作用
  • 批准号:
    23K15529
  • 财政年份:
    2023
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Monocytic-MDSCs as resolution mediators of post-transplant lung ischemia-reperfusion injury
单核细胞-MDSC作为移植后肺缺血再灌注损伤的解决介质
  • 批准号:
    10677290
  • 财政年份:
    2023
  • 资助金额:
    $ 0.45万
  • 项目类别:
Role of Lipid Metabolism in Hepatic Ischemia Reperfusion Injury in Steatotic Livers
脂质代谢在脂肪肝缺血再灌注损伤中的作用
  • 批准号:
    10664736
  • 财政年份:
    2023
  • 资助金额:
    $ 0.45万
  • 项目类别:
ETS2-dependent control in cardiomyocyte ischemia/reperfusion injury
ETS2 依赖性控制心肌细胞缺血/再灌注损伤
  • 批准号:
    10501545
  • 财政年份:
    2022
  • 资助金额:
    $ 0.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了